Tempest Therapeutics (TPST) SC 13G Tempest Therapeutics / Versant Venture Capital VI ownership change

Exhibit 1

JOINT FILING AGREEMENT

The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the timely filing of such statement on Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness or accuracy of the information concerning the others of the undersigned, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate or incomplete. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

Dated: February 11, 2022

Versant Venture Capital VI, L.P.
By:	Versant Ventures VI GP, L.P.
Its:	General Partner
By:	Versant Ventures VI GP-GP, LLC
Its:	General Partner

By:	/s/ Robin L. Praeger
	Robin L. Praeger, Managing Director
Versant Ventures VI GP, L.P.
By:	Versant Ventures VI GP-GP, LLC
Its:	General Partner
By:	/s/ Robin L. Praeger
	Robin L. Praeger, Managing Director
Versant Ventures VI GP-GP, LLC
By:	/s/ Robin L. Praeger
	Robin L. Praeger, Managing Director
Versant Venture Capital IV, L.P.
By:	Versant Ventures IV, LLC
Its:	General Partner
By:	/s/ Robin L. Praeger
	Robin L. Praeger, Managing Director
Versant Side Fund IV, L.P.
By:	Versant Ventures IV, LLC
Its:	General Partner
By:	/s/ Robin L. Praeger
	Robin L. Praeger, Managing Director
Versant Ventures IV, LLC
By:	/s/ Robin L. Praeger
	Robin L. Praeger, Managing Director